Navigation Links
Watson to Present at CLSA/Asia USA Investor's Forum
Date:2/26/2010

MORRISTOWN, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview of the Company's business at the CLSA/Asia Investor's Forum on Tuesday, March 2, 2010 at 4:30 pm Eastern Standard Time at the Westin St. Francis in San Francisco, CA.

This presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com.  

The webcast can also be accessed at the following URL:

http://www.clsa.com/forum/sf10/index.cfm?display=live-streaming&id=10040 

An archived version will be available for 60 days after the live presentation and can be accessed at the same locations.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on urology, women's health. Watson has operations in many of the world's established and growing international markets.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)

SOURCE Watson Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.watson.com

'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The fast-growing cannabis market is expected to create ... According to the 2017 Legal Marijuana Outlook, published by New ... jobs by 2020, with an implied growth rate of more ... accelerating pace of cannabis legalization is considered as the main ... will further create more business ventures and boost the economy. ...
(Date:2/23/2017)... New York , February 23, 2017 ... Cardiac Holter Monitor Market are GE Healthcare, Koninklijke Philips ... of about 48% in the global market in 2015. ... the two key factors assessed to be aiding these ... Market Research states that the players in the global ...
(Date:2/23/2017)... MILFORD, Mass. , Feb. 23, 2017 /PRNewswire/ ... leading partner to global in vitro diagnostics manufacturers ... webinar series titled "Catalyzing Implementation of NGS-Based Tests" ... on March 30, 2017 at 11am Eastern Standard ... series is to highlight the need for improved ...
Breaking Medicine Technology:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Phoenix, announced today that it will soon begin franchising throughout the U.S. starting ... mission to help bring the practice of meditation mainstream. Current Meditation will be ...
(Date:2/23/2017)... , ... ... the perfect opportunity for the nation to come together to ... basketball bracket – with its favorite fruit – apples! To ... apple lovers to join the “Apple Madness” bracket tournament – ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today ... efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at three ... enrolling children across the United States. , “There are currently no approved drugs ...
(Date:2/23/2017)... ... 2017 , ... Carlos Gutierrez has lived his spiritual life hardly ... which is the purpose of everyone in this universe. As Gutierrez sees the need ... Press) attempts to guide readers to expand one’s spiritual life. , “Our Spiritual Truths” ...
(Date:2/22/2017)... ... ... Gevir, a New Zealand-based company that focuses on developing powder and capsule ... Amazon.com, the world’s largest online retailer. , The company was founded in ... treatment for Shelley’s Multiple Sclerosis, which she’d been diagnosed with at 28 years old. ...
Breaking Medicine News(10 mins):